A recent New York Times investigation found that part of a COVID-19 relief bill meant to lower drug prices actually increased costs for 340B providers and some of their most vulnerable patients.
NYT Investigation Highlights Federal Law’s Unintended Harm to 340B Providers
A provision in a 2021 COVID-19 relief bill that sought to lower prescription drug prices has actually made some medications [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.